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ABSTRACT: Long-term exposure of SH-SY5Y human neural cells to retinoic acid (RA) increased the 
binding of [3H]DAMGO and [3H]DPDPE by up to 3-fold compared to membranes of untreated cells. 
In contrast, incubation of the cells with phorbol ester (TPA) selectively up-regulated the binding of 
[3H]DAMGO. RA enhanced the maximal inhibition of cAMP formation in SH-SY5Y cells by both 
DAMGO and DPDPE from 20% for both opioids in control cells to 75% and 50%, respectively. On 
the other hand, the effect of TPA was limited to a marginal increase in the inhibition of cAMP 
formation by DAMGO. Parameters of GTP3PsS binding as well as low-Km GTPase activity revealed 
no deterioration in the structure or function of total G protein in the TPA-treated cells, and initial 
Western blots showed no difference in the cell content of Go. Ongoing experiments are focusing on the 
covalent modification of specific G protein subtypes involved in # and ~ opioid signal transduction in 
SH-SY5Y cells differentiated by TPA. 
METHODS: Human neuroblastoma cells SH-SY5Y were cultured and differentiated with RA or TPA 
for 9-11 days as described (1). Ligand binding was resolved and quantified by computer fitting using 
the statistical program SYSTAT, and the activities of adenylyl cyclase and GTPase were determined by 
a radioligand binding assay and measurement of released 32p, respectively (2). Binding of GTP3Pss (3), 
Western blotting (4), and the determination of protein (3) were implemented as described previously. 
RESULTS AND DISCUSSION: The SH-SY5Y human neural cells were shown to be susceptible to 
functional differentiation by various inducers, including RA and TPA (5). It was also demonstrated that 
exposure of these cells to RA enhanced the inhibition of adenylyl cyclase (AC) by # opioid agonists 
(6,7). The molecular characteristics of opioid signal transduction through receptors, G protein and 
adenylyl cyclase in normal (2) and opioid tolerant (1) SH-SY5Y cells were recently described. In 
investigating the effect of various differentiating agents on these processes, the distinct modulation of 
and ~ opioid receptors by RA and TPA, including a contrasting regulation of # ligand binding and 
receptor coupling by TPA, was observed in cells exposed to these compounds for 9-11 days (Table 1). 
These results corroborate, in part, the previously described enhancement of AC inhibition by # opioids 
in SH-SY5Y cells differentiated with RA (7), and reveal a novel regulation of # opioid signal 
transduction by long-term TPA action: the concurrent receptor up-regulation and effector desensitization. 
In contrast, TPA minimally affected both ligand binding to and effector coupling of the 6 opioid 
receptor. 
TPA has been shown to acutely inhibit the coupling to AC of several inhibitory receptors including the 
opioid (8). Thus, it is plausible to implicate inhibitory G proteins, the common transducers of signal 
transduction in these processes, as the target of TPA action. Indeed, the functional inactivation of Gi 
by TPA-induced phosphorylation has been described (9) and the involvement of PKC, whose activity 
is potently enhanced by phorbol esters, in that process was suggested (8,9). While it was shown that 
differentiation of SH-SY5Y cells by RA did not alter their content of G, or Go, the effect of TPA was 
not investigated in that study (10). 
As shown here, our data on the binding of GTP~/S and opioid stimulation of low-Km GTPase do not 
reveal an impairment in the function of G protein in SH-SY5Y ceils differentiated by TPA (Table 1). 
However, these findings might not disclose possible changes in the relevant G protein subtype: the 
coupling of t~ opioid receptors to adenylyl cyclase is preferentially mediated by Go (4). Furthermore, 
while the preliminary results of Western blots showed no difference in the content of Go following 
differentiation with RA or TPA (not shown), the obtained resolution could be insufficient to reflect 
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partial covalent modification of this G protein subtype. To elucidate the mechanism by which TPA 
induces the concurrent up-regulation of # opioid receptor and desensitization of AC in SH-SY5Y cells, 
ongoing experiments focus on the relationship between Go and PKC, whose activators and inhibitors are 
potent differentiating agents of SH-SY5Y cells (11), and PLC, a Go-selective effector whose activation 
stimulates PKC (12). These potential interrelations illustrate the importance of receptor cross-talk, 
processes by which a given receptor is regulated by others functioning in the same milieu. 
Table 1. Parameters of receptor binding, adenylyl cyclase inhibition and low-Km GTPase stimulation 
by opioids and GTP3,S binding. The saturation binding of [3H]DAMGO and [3H]DPDPE in membranes 
from untreated and differentiated SH-SY5Y cells was resolved by Scatchard analysis (Kd and B.~0. In 
other experiments, intact cells were incubated with unlabeled opioids and their content in cAMP 
determined by radioligand binding. The maximal inhibition of adenylyl cyclase (I~,.x) was related to 
it's activity in the absence of opioids. In separate experiments, membranes were incubated with GT32P 
in the absence and presence of 10/zM opioid. Liberated 32p, corresponding to low-Km GTPase activity, 
was quantified by liquid scintillation counting and expressed as stimulation by opioids (Sin, x). In 
addition, the saturable, specific binding of GTP3,35S was resolved by Scatchard analysis into two sites 







None 0.33 70 ± 3 
TPA 0.37 210 ± 3 
RA 0.45 198 ± 6 
None 3.4 78 + 5 
TPA 2.4 75 ± 3 
RA 2.7 
Kd B ~  SMAX Cell 
(nM) (fmol/mg (%) treatment 
prot) 
1 3 ± 2  
None 
3 8 ± 2  
1 9 ± 3  
TPA 
6 + 3  
1 7 ± 6  
1 5 ± 2  242 ± 13 
Irr~x 
(~) 
2 0 ±  3 
2 6 ± 3  
7 3 ± 5  
1 9 + 4  
1 8 ± 3  
45 ± 5  
RA 
Kd (riM) B ~  
(fmol/mg) 
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